» Articles » PMID: 14656210

Interleukin-1beta (IL-1beta) and IL-6 Modulate Insulin-like Growth Factor-binding Protein (IGFBP) Secretion in Colon Cancer Epithelial (Caco-2) Cells

Overview
Journal J Endocrinol
Specialty Endocrinology
Date 2003 Dec 6
PMID 14656210
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic inflammation is characterised by modifications in cytokine concentrations, whereas growth is mainly dependent on the GH-IGF axis. IGF-I bioavailability is modulated by a family of IGF-binding proteins (IGFBPs). The aim of the present study was to evaluate the interactions among interleukin-1beta (IL-1beta), IL-6 and IGFBP secretion by intestinal cells to assess whether cytokines modulate IGFBP secretion, and in turn IGF-I and IGF-II bioavailability. The human colon carcinoma derived cell line Caco-2 was used as an in vitro model for its capacity to differentiate spontaneously. Experiments were carried out on day 4 (undifferentiated state) and day 14 (differentiated state) after plating. Carcinoembryonic antigen (CEA) was used as a marker of differentiation and increased in the conditioned media (CM) from days 4 to 14 (0.2+/-0.01 ng/ml per 10(5) cells vs 3.3+/-0.2 ng/ml per 10(5) cells, P<0.05). IGFBP-2 and IGFBP-4 secretion decreased concomitantly. Cells were stimulated with IL-1beta and IL-6 at 1, 10 and 50 ng/ml, and with IL-1beta and IL-6 in combination at the same dose of 1 and 10 ng/ml. IGF-I at 50 ng/ml was used as a control. Caco-2 cells expressed and secreted mainly IGFBP-2 and IGFBP-4 into the CM. On day 4, IL-1beta (1 ng/ml) and IL-6 (10 and 50 ng/ml) reduced IGFBP-2 by 29+/-8%, and by 32+/-9 and 38+/-8% respectively (P<0.05). IGFBP-4 was also reduced by IL-1beta at 1 and 50 ng/ml (-14+/-4% and -46+/-11% vs serum free medium (SFM) respectively, P<0.05), and IL-6 at 50 ng/ml (-46+/-15%, P<0.05). Both IGFBP-2 and IGFBP-4 were reduced by IL-1beta and IL-6 in combination at 1 and 10 ng/ml (P<0.05). On day 14, IGFBP-2 band intensity was reduced at 10 ng/ml of IL-1beta (-22+/-15% vs SFM, P<0.05) and at 50 ng/ml of both cytokines (-33%+/-8% and -13%+/-13% vs baseline respectively, P<0.05). IGFBP-4 band intensity decreased with 10 and 50 ng/ml of IL-1beta (-35+/-11% and -46+/-15% vs SFM respectively) and IL-6 (-36%+/-10% and -46+/-15% vs SFM respectively). IL-1beta and IL-6 in combination at 1 and 10 ng/ml reduced both IGFBP-2 and IGFBP-4.In conclusion, IGFBP-2 and IGFBP-4 secretion in CM decreased with Caco-2 cell differentiation. IGFBP-2 and IGFBP-4 were significantly decreased by IL-1beta and IL-6 treatment in both the undifferentiated and differentiated state. Furthermore, these cytokines increased cell proliferation whereas total protein content was significantly reduced only at the higher concentrations of IL-6 and IL-1beta. These findings suggest that interleukins modulate the IGF-IGFBP system in Caco-2 cells in vitro.

Citing Articles

High systemic inflammation response index (SIRI) level as a prognostic factor for colorectal cancer patients after curative surgery: a single-center retrospective analysis.

Hayama T, Ochiai H, Ozawa T, Miyata T, Asako K, Fukushima Y Sci Rep. 2025; 15(1):1008.

PMID: 39762444 PMC: 11704263. DOI: 10.1038/s41598-024-84991-z.


Discovery of plasma proteome markers associated with clinical outcome and immunological stress after cardiac surgery.

Bello C, Filipovic M, Huber M, Flannery S, Kobel B, Fischer R Front Cardiovasc Med. 2024; 10:1287724.

PMID: 38379859 PMC: 10876477. DOI: 10.3389/fcvm.2023.1287724.


The Insulin-like Growth Factor System and Colorectal Cancer.

Gligorijevic N, Dobrijevic Z, Sunderic M, Robajac D, cetic D, Penezic A Life (Basel). 2022; 12(8).

PMID: 36013453 PMC: 9410426. DOI: 10.3390/life12081274.


Fasting Serum IGFBP-1 as a Marker of Insulin Resistance in Diverse School Age Groups.

Bhangoo A, Gupta R, Shelov S, Carey D, Accacha S, Fennoy I Front Endocrinol (Lausanne). 2022; 13:840361.

PMID: 35586622 PMC: 9108162. DOI: 10.3389/fendo.2022.840361.


Reposition of the anti-inflammatory drug diacerein in an colorectal cancer model.

Abdel-Latif R, Wadie W, Abdel-Mottaleb Y, Abdallah D, El-Maraghy N, El-Abhar H Saudi Pharm J. 2022; 30(1):72-90.

PMID: 35145347 PMC: 8802128. DOI: 10.1016/j.jsps.2021.12.009.